Presentations

02_Vijayalaxmi

Cytogenetic studies in mammalian somatic cells exposed to radiofrequency radiation: past, present and future. Vijayalaxmi

03_Buschmann

Conclusions from animal studies. Jochen Buschmann

05_Berg-Beckhoff

Conclusions from epidemiological studies. Gabriele Berg-Beckhoff

07_Obe_presentation_1

Validity and reliability of genotoxic studies for cancer risk assessment. Günter Obe

08_Lloyd

Chromosomal aberration analysis. Is it informative for RF-EMF exposure? David Lloyd

09_Obe_Durante_CA and Cancer Incidence

Doing risk assessment based on genetic data Marco Durante (excerpt from talk given by Günter Obe)

10_Kiefer

Comparative risk assessment with ionizing and nonionizing radiation. Jürgen Kiefer

11_Herceg

Importance of epigenetic changes in cancer. Zdenko Herceg

12_Klein-Hitpass

Validity and reliability of current omics studies for cancer risk assessment (EMF studies). Ludger Klein-Hitpass

13_Nürnberg

Future developments in omics technologies for cancer risk assessment. Peter Nürnberg

14_Stelzl

Future developments of proteomics for cancer risk assessment. Ulrich Stelzl

15_Portier

Omics for risk assessment: pathways to disease. Chris Portier

16_Morgan

What have omics taught us about risks associated with exposure to ionizing radiation? William Morgan

17-1_Meltz_Presentation

Can extrapolation of “omic” data be applied appropriately to radio frequency field bioeffects? Martin Meltz

17-2_Meltz_Genotoxicity_2006

RF and Genotoxicity - review on studies til 2006

18_Leszczynski

The RF-EMF case I: Usability of “Omics”-Approach in Risk Assessment of RF-EMF. Dariusz Leszczysnki

19_Franke

The RF-EMF case II: Genomics Approach. Helmut Franke

20_Marchant.

Omics and the Precautionary Principle. Gary Marchant